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Leishmania is an obligate intracellularparasite that survives within the phagolyso-
somes ofits vertebrate hosts' macrophages(1-3). Once the promastigote form ofthe
parasite is introduced into the host tissue by a feeding sandfly, it must gain entry
into a macrophage in order to survive and develop into the amastigote form. The
initial attachment ofLeishmania promastigotes to the macrophage is receptor medi-
ated (4-6), however, theidentityoftheligandsontheparasiteandtheircomplemen-
tary receptors on the surface ofthe phagocyte is not known. Since some receptors
on the macrophage surface initiate a microbicidal response when complexed with
theirligand, and others do not (7-9), onepossible meansby which theparasitemay
increase its chance of successfully infecting the macrophage is in the "choice" of
receptor(s) used during phagocytosis.
Todate, two ligands onthe surfaceofthe promastigote capable ofindependently
mediatingattachment to themacrophage surface have been identified and isolated.
These are the promastigote surface glycoprotein gp63 (10) and the promastigote
lipophosphoglycan(11). The receptorsforthesespecific ligands have not asyet been
identified,but severalstudiesconductedonintact parasiteshave implicated avariety
ofreceptorsthat mayfunction inthebindingofpromastigotestomacrophages. These
receptors include the mannosyl/fucosyl receptor (5), a receptor for nonenzymati-
cally glucosylatedmoeities (12), and the complement receptor type3 (CR3) (13-15).
Paradoxically, CR3 recognizes Leishmaniapromastigotes intheabsence ofexogenous
complement. This led to the proposal that the macrophages itself secretes comple-
mentcomponents thatthendepositonthe promastigote surface(13, 14). Inthepresent
study, we demonstrate thatCR3 is the receptor for the promastigote surface glyco-
protein gp63 and that CR3binds directly to aregion ofgp63 containing theamino
acid sequence Arg-Gly-Asp (R G D).
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Materials and Methods
Cells.
￿
All Leishmania lines were maintained as promastigotes in Semi-defined medium
'79 (16) supplemented with 10% heat-inactivated FCS. The Leishmania strains used in this
study were L. mezicana (MNYC/BZ/62/M379), L. major (NIH173,WR401), and L. donooani
(13138). All isolates were used for experiments within 8 wk oftransformation from amastigotes,
or from frozen stabilates of freshly transformed parasites.
Human monocytes were isolated from buffy coats on a Percoll gradient and cultured in
RPMI plus 12.5% human serum in Teflon beakers as detailed previously (17). These cells
were used after 4-10 d in culture and are referred to as macrophages (MO) in this study.
Polymorphonuclear leukocytes were isolated from fresh human blood by the method of En-
glish and Anderson (18).
mAbs.
￿
The mAbs used in this study are described in Table I. TueL3.2 and TueL3.9 were
present in ascites fluid, but all other antibodies were purified Igs. All the mAbs used were IgGs.
Isolation of gp63 and LPG.
￿
The promastigote glycoprotein gp63 was isolated by Con A
chromatography ofa detergent extract from a crude membrane preparation as described pre-
viously (10, 24). The gp63-containing fraction was then further fractionated by FPLC anion
exchange chromatography on Mono Q-Sepharose, rather than the QAE Sephadex used in
the earlier studies. The purity ofall antigens was confirmed by SDS-PAGE before use. Soluble
gp63, lacking the phospholipid anchor, was produced by incubating gp63 bound to Con
A-Sepharose, with 5 U/ml phospholipase C from Bacillus ceres(type III; Sigma Chemical Co.,
St. Louis, MO). This phospholipase preparation is contaminated with PIPLC-specific lipase
activity capable of removing gp63's PI anchor. After digestion, the enzyme and the cleaved
tail were washed from the column, and the gp63 fraction was eluted as described above. Gp63
was further purified by anion exchange chromatography as described, in the absence of de-
tergent.
The lipophosphoglycan was purified by differential solvent extraction by the procedure
of Orlandi and Turco et al. (25, 26). Both gp63 and the lipophosphoglycan o£ Leishmania
promastigotes (LPG) were isolated from stationary phase cultures.
Preparation oftheLigand-bearing Particles.
￿
Solid 5-urn diameter beadsbearing defined ligands
were made by a modification ofthe technique ofGoldstein and Mescher (27), who used HPLC
reverse-phase gel matrix as support for artificial membranes bearing class 1 antigens. In our
hands, the lipid mixture used in the original paper rendered the particles "sticky" to MO.
However, the substitution ofthe syntheticphospholipid dipalmitoylphosphatidylcholine (DPPC)
for the original phospholipid mixture effectively reduced this behavior. DPPC has a phase
transition temperature of 41°C, which means that at the experimental temperature, the lipid
membrane is relatively immobile. This apparently reduces the likelihood ofthe bead surface
binding or fusing with the MO membrane.
The coated particles, or "pseudocytes" (27), were prepared as follows. 25 mg (N5 x 108
particles) o£ 5 um ODSI reverse phase beads (Phase Separation) were suspended in 1 ml of
PBS containing 10 mg/ml n-octylglucoside (PBS-NOG). 10 mg of DPPC (Sigma Chemical
Co.) was dissolved in 1 ml of PBS with 50 mg/ml n-octyl glucoside. Theligands, LPG and
gp63, were then prepared at a 200-pg/ml concentration in PBS-NOG, and trace amounts
of ligand metabolically labeled with [3H]galactose (LPG) or ("S]-methionine (gp63) were
added to the preparations. In a typical preparation, 20 pl of the bead suspension was mixed
with 25 gl of DPPC solution, ligand was then added to the desired concentration, and the
total volume increased to 500 gl with extra PBS-NOG. The mixture was then placed in dial-
ysis tubing from which all air was excluded. The tubing was anchored in a horizontal position
to avoid unequal distribution of the beads and was then dialyzed at 4°C against PBS over-
night. The beads were washed twice by gentle centrifugation and resuspended at 10'/ml in
fresh PBS. The percentage incorporation was calculated by counting the radioactivity in an
aliquot ofthe beads. In preliminary experiments, the ratioofsurface-exposed ligand vs. total
incorporated ligand was calculated by incubating the beads in radiolabeled mAb and cen-
trifuging the particles through a sucrose cushion. The percentage ofexposed ligand was con-
sistently --60%.
Antibody-coated beads (BIgG) were prepared from the gp63-containing beadsby incuba-RUSSELL AND WRIGHT
TABLE I
mAbs Used in This Study
mAb
￿
Antigen
￿
Reference
OKM10
￿
a chain of CR3 (CD11b)
￿
(23)
TSI/22
￿
a chain of LFA-1 (CD11a)
￿
(21)
LeuM5
￿
a chain of p150,95 (CD11c)
￿
(22)
IB4
￿
p chain of CR3, LFA-1, p150,95 (CD18)
￿
(23)
W6/32 HLA
￿
(19)
AIA5
￿
p chain of VLA antigens
￿
(20)
TueL3.2
￿
Leishmania gp63
￿
(24)
TueL3.9
￿
Leishmania gp63
￿
(24)
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tion ofthe particles in ascites fluid (2% in PBS) from two hybridoma cell lines, TueL3.2 and
TueL3.9, secreting IgG1 antibodies against different epitopes on gp63.
Sheep erythrocytes (E) coated with antibody (EA) or C3bi (EC3bi) were prepared as de-
scribed previously (17).
TheAttachmentofLigand-bearing Particles to HumanMO.
￿
Monolayers of MO were produced
as follows. Cells were suspended at 106/ml in PBS with divalent cations (1 mM CaC12 and
0.5 MM MgC12), 3 mM glucose, and 0.5 mg/ml human serum albumin. The cells were
added in 5-pl aliquots to the wells of Terasaki tissue-typing plates and left to settle for 1 h
at 37°C. In down-modulation experiments, the Terasaki wells had been previously coated
with antibody by incubating the respective wells with 5 ttl of PBS containing 25 pg/ml of
the various anti-receptor mAbs for 1 h at 20°C. The monolayer was washed in PBS and rinsed
in a final change of DGVB with divalent cations (2 .5 mM veronal buffer, pH 7.5, 75 mM
NaCl, 2 .5% dextrose, 0.05 gelatin, 0.15 mM CaC12, and 0.5 MM MgC12). In experiments
involving the use of soluble inhibitors, such as peptides, the inhibitors were introduced to
the Terasaki plates at this point, immediately before the addition ofthe ligand-bearing particles.
Attachment of ligand-bearing particles to MO was determined by adding 5 x 104 coated
beads or 2 .5 x 105 erythrocytes per well and incubating for 15 or 45 min, respectively at
37°C. The attachment of the particles to the MO was then scored by phasecontrast micros-
copy as detailed previously (17).
Synthetic FI!ptides.
￿
Peptide L10 (LGGALQAGDV), based on residues 402-411 ofthe y chain
of human fibrinogen, was synthesized by Peninsula. An inactive analogue of L10, AcLIO,
was prepared by acetylating lysine 406 as described (28). Both L10 and AcL10 were repurified
by HPLC on a reverse-phase column. Peptide G15 (GQQHHLGGAKQAGDV) based on
residues 398-411 of the y chain of fibrinogen was purchased from Sigma Chemical Co.
GRGDSP and GRGDESP were a generous gift from Dr. M. Pierschbacher, La Jolla, CA.
Pep63 was synthesized from residues 365-385 of the gp63 amino acid sequence (RLLPGG-
LQQGRGDAVGPERGC) by Dr. D. Schlesinger, N.Y.U. Medical Center, NY.
Results
The Binding ofgp63 Beads to HumanMO.
￿
Purified gp63 was incorporated into a
phospholipid monolayer supported by 5-pm beads. Fig. 1 illustrates the effect ofin-
creasing gp63 concentration on the binding of the beads to monolayers of MO. A
density of 1.25 x 103 molecules/pmt was sufficient to facilitate the binding of at least
one bead to 65 % of the cells. Increasing the ligand density above this level caused
a marked increase in the number of beads bound per MO. At a density of 6.35 x
103 molecules/pmz, virtually all the MO had bound multiple beads (at least six
beads per cell). All subsequent experiments to identify the MO receptor for gp63
were performed with beads containing 3-7 x 103 molecules/pmt.282
￿
LEISHMANIA gp63 BINDS TO COMPLEMENT RECEPTOR TYPE 3
401-
20
o" 10 to
LIGAND DENSITY
( log scale )
10
FIGURE 1. Binding of gp63
-)
￿
beads to MO. MO were in-
cubatedwith beadsbearingvar-
ious densities of gp63, plotted
above as molecules of gp63/
JIM2, and the percentage of
cells with at least one attached
bead and the total number of
beads bound per 100 cells was
200
￿
measured.Thevertical linesas-
sociated with each point indi-
cate the SD. These values are
100
￿
theaverage from threeindepen-
dent experiments.
Phase-contrast microscopical examination oftheMO after coincubation with the
ligand-bearing beads revealed many gp63 beads bound to the surface ofthe phago-
cyte, but none appeared to have been internalized (Fig. 2A). In contrast, gp63 beads
incubated in IgG against gp63 before addition to the MO monolayers were phago-
cytosed by the MO (Fig. 2 B). Internalization of beads was also observed when the
other promastigote ligand, LPG, was reconstituted onto the bead surface together
with gp63 (datanot shown). We therefore conclude that occupation ofthe receptor
forgp63 is not sufficient stimulus to induce phagocytosis, at leastat the ligand densi-
ties examined. The addition of another ligand, or a suitable opsonin such as IgG,
to the bead surface triggers ingestion.
Down-modulationofReceptorsonMObymAb-coatedSurfaces.
￿
MO were plated on tissue
culture surfaces precoatedwith mAbs ofknownspecificity. Previous work has shown
that surface-bound mAbs cause depletion oftarget antigens from the accessible, upper
portion of the cell plasmalemma (23). The attachment of gp63 beads was strongly
inhibitedby platingthe MO onto antibodies specific foreither the a chain(OKM10)
or the R chain (IB4) of CR3 (Fig. 3). gp63-specific attachment, i.e., the binding at-
tributable to the ligand on the bead surface, was inhibited by >85% by both these
antibodies. In parallel studies, anti-CR3 antibodies mediated a similar inhibition
of binding of EC3bi to the MO. Antibodies against the related proteins LFA-1 and
p150,95 did not affect attachment of any particle. Similarly, antibodies against the
R chain of theVLA family of antigens, which includes the fibronectin receptor, and
against HLAmolecules, did not affect the attachment ofeither gp63- or C3bi-bearing
particles. None of the absorbed antibodies reduced the binding of antibody-coated
gp63 beads, indicating that the reduction in attachment of gp63 beads by anti-CR3
antibodies was caused by depletion of accessible CR3.
Thebindingofligand-bearing particlesto MO plated onto human serum albumin,
IgG, and collagen was also examined. None of these proteins altered the levels of
bindingofany oftheparticles. Fibronectin-coated surfaces, on the otherhand, caused
a small increase in the binding of both EC3bi and gp63 beads (data not shown)
in afashionconsistent with previous observations on CR3-mediated attachment (29).
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FIGURE 2.
￿
Bindingand phagocytosis ofligand-bearing beads . Monolayers ofMO were incubated
with ligand-bearing beads for 15 min at 37°C as described in Materialsand Methods . gp63 beads
bind to the surface ofcultured human MO, butno internalization is evident (A) . However, gp63
beads coated with IgG anti-gp63 appeared to be phagocytosed by theMO (B) .
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FIGURE 3 .
￿
Modulation of receptors by
surface-bound mAbs. Monolayers ofMO
wereestablished on plastic surfaces coated
with a variety of mAbs . These cells were
then incubated together with ligand-
bearing beads, and the number of beads
bound per 100 cells were measured. The
antibodies against HLA (W6/32), VLA
(AIA5), LEA-1 (TS1/22), and p150/95
(LEUM5)hadno effect on the attachment
of any of the particles . Both antibodies
against CR3 (OKM10 andIB4) reduced
the binding of EC3bi and gp63 beads
(Bgp63).The attachment ofbeads without
ligand (Bcon) andgp63 beads coated with
IgG (BIgG) was unaffected by the anti-
bodies. The vertical lines indicate theSD.
These results were confirmed in six inde-
pendent experiments .
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All these peptides were used in the competitive inhibition assay that is described in Figs. 4 and 5.
These results indicate that the fibronectin receptor is not involved in the binding
of gp63 to the MO surface.
Gp63 beads also bound to polymorphonuclear leukocytes. As with the attachment
to MO, this binding was mediated by CR3, and could be inhibited by soluble OKM10
antibody (data not shown).
Inhibition ofgp63-mediated Binding to MO by Synthetic Peptides ContainingArg-GlyAsp
(R G D) and Related Sequences. CR3 is known to recognize a region of C3bi that
contains the triplet Arg-Gly-Asp (R G D) (30). Since gp63 contains an R G D se-
quence at amino acid residues 375-377 (31), it is possible that CR3 could recognize
this portion ofthe protein. We addressed this question experimentally by examining
the effect of a synthetic 21-amino acid peptide, spanning residues 365-386 of the
gp63 sequence (see Table II) on the binding of gp63 beads and EC3bi to MO.
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TABLE II
The Sequence of Synthetic Peptides Used in This Study
FIGURE 4.
￿
Competitive inhibition of binding of
ligand-bearing beadswith syntheticpeptides. Mono-
layers of MO were established and incubated with
ligand-bearing beadsin thepresence ofdifferent syn-
thetic peptides. All peptides were added to a final
concentrationof2mg/ml. Thepeptides that inhibited
binding of EC3bi also inhibited the attachment of
gp63 beads(Bgp63). Thesepeptides, pep63andL10,
are based on sequences from gp63 andfibrinogen,
respectively (see Table II). None of the other pep-
tides affected the attachment of any of the ligand-
bearingbeads. In addition, the gp63 beads coated
with IgG(BIgG) andthebeadswithoutligands (Bcon)
were also unaffected by thepeptides. These results
were obtained in threeseparate experiments each run
in duplicate.
Peptide
designation Sequence
Receptor
inhibited
pep63 RL L PGGLQQG RGD AVGP ERGC CR3
L10 LGGAKQ AGD V CR3
AcL10 L G G A(acK)Q A G D V No inhibition
G15 G Q QH H L G G A K Q A G D V CR3
GRGDSP G R G D S P FnR
GRGESP GRGES P No inhibitionw
n
0
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FIGURE 5.
￿
Inhibition of binding of ligand-bearing beads
withsynthetic peptides. Monolayes ofMO were incubated
with either EC3bi or gp63 beads (Bgp63) in the presence
of increasing concentrations of synthetic peptides, pep63,
and G15. Both peptides mediated comparable levels of in-
hibition ofthe binding ofboth particles. This graph shows
the result from one experiment conducted in triplicate.
Similar results were obtained in two independent ex-
periments.
Soluble pep63 effectively inhibited the binding of both gp63 beads and EC3bi
to MO (Fig. 4). Half-maximal inhibition was achieved at til mg/ml (5 x 10-4 M)
for both gp63 beads and EC3bi (Fig. 5). Parallel studies showed that, at the concen-
trations used, the peptide had no effect on the binding of IgG-coated gp63 beads,
thus confirming the specificity ofthe observed inhibition. Moreover, synthetic pep-
tides based on the R G D-containing region of fibronectin (32) failed to affect the
binding of either gp63 beads or EC3bi. These data indicate that gp63 contains an
aminoacid sequence that interacts directly with CR3. In addition, these results confirm
our finding that the fibronectin receptor does not function in the binding of gp63
by MO.
Recent studies have shown CR3 binds not only to the R G D-containing region
of C3bi, but also to a related sequence in fibrinogen (Wright, et al., manuscript
in preparation). CR3 recognizesthe sequence K QA G D V present in the fibrinogen
y chain, and peptides based on this sequence are particularly effective competitive
inhibitors of EC3bi binding. The peptide L10 (L G G A K QA G D V) inhibited
the binding ofboth EC3bi and gp63 beads to MO (Fig. 4). In contrast, the acetylated
form ofthe peptide AcL10, which had previously been shown to be unable to inhibit
the binding of EC3bi (Wright, S.D., manuscript in preparation), had no effect on
the ability ofeither gp63 beads or EC3bi to bind to MO (Fig. 4). We used a slightly
longer peptide based on the fibrinogen sequence, G15, to demonstrate that the con-
centration of peptide required to produce effective inhibition of binding was com-
parable for both EC3bi and gp63 beads (Fig. 5). These findings further support the
conclusion that the inhibition of binding ofgp63 beads by synthetic peptides is due
to competition for the complement binding site on CR3 .286
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Inhibition of bindingof ligand-bearing
particles by soluble gp63. Monolayers of MO were
incubatedwith ligand-bearingparticlesin thepres-
ence of increasing concentrations of gp63, made
solubleby theremovalofthephospholipid membrane
anchor. gp63 inhibited the binding of both EC3bi
and gp63 beads(Bgp63)to MO. Half-maximal inhi-
bition of binding occurred at -400 pg/ml of gp63
for both particles. gp63 had no effect on either the
negative control, particleswith no ligandadded(Con-
trol), or thepositive control, gp63 beadscoated with
IgG (BIgG). This graph shows the result from one
experiment conducted in triplicate. Comparable
results were obtained in three independent ex-
periments.
The above data indicate that gp63 contains a sequence that can interact directly
with CR3. To verify that the R G D-containing region is accessible on the native
molecule, gp63 was made soluble by removal of the phospholipid anchor known to
retain the protein in the membrane (33). Soluble gp63 competitively inhibited the
attachment of both gp63 beads and ofEC3bi to macrophages (Fig. 6). Half-maximal
inhibition occurred at -400 gg/ml (6.7 x 10-6 M). Thus on a molar basis, intact
soluble gp63 is -75-fold more effective than pep63 in inhibiting gp63 bead and EC3bi
attachment.
The Effect ofSoluble LPG and pep63 on the Binding and Uptake of Whole Promastigotes
and Amastigotes. The attachment and ingestion of whole parasites by human MO
in the presence of the promastigote surface antigen LPG and pep63 was examined.
The parasites used included L. mexicana promastigotes, from both logarithmic and
stationary phase cultures, and amastigotes. Both pep63 and LPG independently sup-
pressed the attachmentofpromastigotes to the MO (Fig. 7). Simultaneous addition
ofboth ligands caused enhanced inhibition, suggesting that the ligands occupy dis-
crete binding sites. Similar results were obtained using L. donovani and L. major
promastigotes, indicating that this dual recognition is not species specific (data not
shown). Despite the marked effect these inhibitors had on the attachment of the
promastigote stage, the binding ofL. mexicana amastigotes was unaffected. This re-
sult demonstrates that the inhibition caused by pep63 and LPG in the promastigote
experiments is unlikely to be due to toxicity, and that the amastigote possesses addi-
tional or alternative means of binding to and entering phagocytes.
Discussion
The participation of gp63 in the attachment of promastigotes to MO is known
from previous studies, both in our own (10) and other laboratories (34). Since intact
promastigotes possess an additional molecule (LPG) that also functions in attach-
ment to MO (11), it has not been possible to dissect the individual contributions
ofthesetwo components. We therefore developed a bead capable ofcarrying a single
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FIGURE 7.
￿
Inhibition ofparasite attachmentto MO
by pep63 and LPG. Monolayers of MO were in-
cubatedwith promastigotes from log or stationary
phase cultures, or with amastigotes in the presence
of LPG or pep63. The concentrations chosen, 2
mg/ml pep63 and 500 pg/ml LPG, were twicethe
concentration required to producehalf-maximal in-
hibitionin preliminary experiments. Both inhibitors
depressed binding of promastigotes, an effect that
was summated in preparations containing both
ligands. Neitherligand had an effect on bindingof
amastigotesto MO. Thevaluesrepresenttheaverage
from twoindependent experiments runin triplicate.
promastigote ligand, gp63, and studied the interaction between the gp63-bearing
particle and the MO surface. In the initial experiments, the binding of gp63 beads
to MO was examined as a function of increasing ligand density (Fig. 1). Maximum
binding occurred at ti6-7 x 103 molecules/gm2, a density similar to the theoret-
ical density of the ligand on the promastigote surface (6 x 103 molecules/Pm2). This
was calculated assuming a cell surface area of 80 wm2 and 500,000 copies/cell (35).
mAbs against CR3 have been reported to reduce the binding of Leishmania
promastigotes to MO (13-15). Since CR3 expresses separate binding sites for both
protein (C3bi) and for other ligands, such as bacterial LPS andHistoplasma (36, 37),
the receptor could recognize Leishmania by binding gp63, LPG, or both. To deter-
mine if CR3 recognizes gp63, substrate-bound mAbs were used to selectively de-
plete CR3 from the upper surface of the cell. Such down-modulation of CR3 with
either IB4 or OKM10 caused an 85% reduction in the binding of gp63 beads. A
comparableinhibitionofbinding ofEC3bi was observed in parallel experiments (Fig.
3). These results demonstrate that CR3 is the primary receptor responsible forbinding
gp63.
CR3 is a member ofa large family ofstructurally homologous, adhesion-promoting
receptors termed "integrins" (38, 39). This family includes the fibronectin receptor,2$$
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gpIIb/III ofplatelets, CR3, and the closely related leukocyte proteins LFA-1 and
p150,95. Nearly all integrins bind ligands that contain RGD, or a similar amino
acid sequence. For example, CR3 recognizes a region of C3bi that contains the
RG Damino acid triplet (30). Since the deduced amino acid sequence ofgp63 was
found to contain the triplet RG D at residues 375-377 (31), the existence ofwhich
was predicted from immunological data (40), we asked whether this sequence was
thetarget recognized byCR3. A syntheticpeptidecomprised of21 aminoacids span-
ning the RGD region ofgp63 effectively inhibited the binding ofboth gp63 beads
and EC3bi to MO (Figs. 4 and 5). Additional experiments demonstrated that pep-
tides previously shown to inhibit the binding ofEC3bi to MO were also able to in-
hibit the attachment of gp63 beads (Table II and Fig. 4). These results show that
gp63 contains a sequence that binds directly to CR3, and that the binding site in-
volved is the same binding site that recognizes C3bi.
To determine ifthe R GD-containing region ofgp63 was accessible on thenative
molecule, we first removed thephospholipid membrane anchor. Theresultingsoluble
gp63 competitively inhibitedthe attachment ofboth gp63 beads and EC3bi to MO
(Fig. 6). Interestingly, gp63 was 75-fold moreeffective than pep63 at mediating in-
hibition. We assume that gp63 is a more avid ligand for CR3, because the intact
protein holds the R G D-containing region in a favorable configuration.
Although gp63 is recognized by CR3, it is not bound by other integrins on the
MO surface. Down-modulation of LFA-1, p150,95, or the fibronectin receptor by
mAbsdidnotaffect bindingofgp63 beads(Fig. 3). Platingofthe cellsonfibronectin
also failed to decrease binding. Finally, peptides based on the R G D-containing
sequence of fibronectin (G R G D S P) did not affect the binding of gp63 beads
(Fig. 4). The datais consonant with previous findings that CR3 does not recognize
fibronectin or synthetic peptides based on the fibronectin sequence (30, 41). The
specificity shown by gp63 for CR3 may, in consequence, aid in targetting the
promastigote to the MO.
Other investigators have demonstrated that CR3 plays a role in the binding of
whole promastigotes to macrophages (13-15). To explain the ability of antibodies
against CR3 to block parasite binding in the absence of exogenous complement,
Blackwell and coworkers (14) have proposed that MO secrete complement compo-
nents that opsonize the promastigotes. While we cannot rule out a role for autoop-
sonization under some circumstances, several observations indicate that opsoniza-
tion does not underlie the binding of gp63 to CR3 described in this study. Strong
binding was observed within 15 min, during which time little secretion is likely to
occur (42). Furthermore, weobserved strong, anti-CR3-inhibitable bindingtoPMN,
a cell type that has a very low rate of protein synthesis and has not been shown to
produce C3. Finally, the bindingofgp63 beads and EC3bi was inhibited by soluble
gp63 (Fig. 6), presumably through competition for the same binding site on CR3.
We therefore believe that a direct interaction between CR3 and gp63 is sufficient
to explain theknownCR3 dependence ofbindingofLeishmania promastigotes toMO.
Blackwell and colleagues (14) have also observed that Fab fragments from poly-
clonal anti-C3 antibody blocked the binding ofpromastigotes to MO and bound
to the parasite surface during internalization (14). Since gp63 and C3bi contain a
related amino acid sequence that is recognized by CR3, it is possible that the anti-
C3 antibody bound to the RGD region ofgp63, not C3. The existence ofa cross-RUSSELL AND WRIGHT
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reactive epitope is supported by current results showing that anti-pep63 antibody
recognizesboth gp63 andthe achain ofC3 (Russell et al., manuscriptin preparation).
Although our experiments demonstrate that CR3 binds gp63, it should be noted
thatgp63 beadsbound by MO were notphagocytosed (Fig. 2). This finding is con-
sistent with previous observations showing thatCR3 on resting MO binds but does
not cause internalization of EC3bi (17). These results indicate that promastigotes
require additional, or alternative, ligandsthat bind to receptors ontheMO surface
topromotephagocytosis orto enable CR3toinitiate phagocytosis. Apreviousstudy
has implicated LPG in the attachment ofpromastigotes to MO (11). Two observa-
tions in the present study support a role for LPG in host cell entry. The addition
ofLPG to the surfaceofgp63 beads inducedthe phagocytesto internalize the parti-
cles. Second, binding ofpromastigotes can be partially inhibited by soluble LPG,
andthiseffect is additivewith the inhibitory effect ofpep63(Fig. 7). The significance
of gp63 and LPG as the principal ligands for MO is highlighted by their extreme
abundance on the promastigote surface; 5 x 105 copies ofgp63 (35) and 106 copies
of LPG (Russell, D. G., unpublished results).
Leishmania promastigotes havebeen shownto differentiate in culturefromanonin-
fective form of promastigote in actively dividing cultures, to an infective form in
stationary phase cultures (43, 44). This differentiation is accompanied by changes
on the promastigote surface. The surface expression ofgp63 is increased (45), and
LPG undergoes some structural modification (46) during the differentiation. De-
spitethesechanges, ourinhibition experimentsconducted withwhole promastigotes
(Fig. 7) indicate that both infective and noninfective stages use LPG and gp63 to
attach to MO. This isconsistentwith previous observations showingthat infectivity
was not dependent on the ability ofthe parasite to bind to, and be internalized by,
MO (44).
These results call into question the exact role ofcomplement in the infection of
MO by promastigotes. Thepredominant form ofC3 deposited on the promastigote
by serum is Cab, not C3bi (47), thus, raising the possibility that the C3b receptor
(CR1) may also participate in the uptake ofpromastigotes opsonized with comple-
ment. Mosser and Edelson (48) have proposed that complement is necessary for
the intracellular survival of L. major promastigotes. Our data, however, show that
complementis not necessaryforthe bindingofpromastigotes to MO, andthat gp63
binds directly to CR3. The relative contribution ofcomplement, and the endoge-
nous ligands gp63 and LPG, to the infection of MO is currently under study.
Summary
The major surface glycoprotein of Leishmania promastigotes, gp63, was isolated
and reconstituted into a lipid membrane immobilized on the surface of 5-pm-di-
ameter silica beads. These beads bound to the macrophage (MO), and the extent
ofbinding correlatedwith the densityofgp63 onthebead. Thebeadthus facilitated
analysis ofthebindingspecificity ofa single ligand, gp63, without contribution from
othermolecules present on the surface ofintact promastigotes. Plating ofMO onto
substrates coated with antibodies directed against several cell surfacereceptorsindi-
cated that the complement receptor CR3 was necessary for binding gp63.
CR3 recognizes a portion ofC3 that contains the sequence R GD. Since gp63290
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also contains such a sequence, we tested the ability of a synthetic peptide based on
the R G D-containing region of gp63 to inhibit the binding of gp63 beads . The
RG D-containing peptide fromgp63 inhibited the binding of both gp63 beads and
EC3bi toMO. Similarly, peptides previously shown to inhibit the binding ofC3bi
also inhibited the attachment of gp63 beads . The synthetic peptide from theRG
D region of gp63 also reduced the binding of intact promastigotes to MO. These
results indicate that gp63 binds directly to CR3 .
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